Psychiatric Symptoms in Patients Receiving Dolutegravir. - Wikidata - wikimedia - TriplyDB

Psychiatric Symptoms in Patients Receiving Dolutegravir.

Psychiatric Symptoms in Patients Receiving Dolutegravir.

http://www.wikidata.org/entity/Q37659135

about

Out of focus: tailoring the cascade of care to the needs of women living with HIV.Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1.Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk.Dolutegravir plus abacavir/lamivudine works in adolescents, but size matters.A retrospective clinical audit of general practices in Australia to determine the motivation for switch to dolutegravir/abacavir/lamivudine and clinical outcomes.Severe depression as a neuropsychiatric side effect induced by dolutegravir.Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015.A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population.

P2860

Q40062892-E1144398-3171-46C2-91F6-6E2CBF43B9A8 Q41711863-20717846-9104-492E-A99C-947B120079F7 Q47145824-F0C5A08D-12AA-4A9D-84AE-D4B176E5DEDA Q47178545-FAFAB86A-EF8A-494F-9893-A8DA4738B640 Q47321307-A2408320-A9EA-4CB6-A344-494811DF0B17 Q47815951-655CAFFA-775A-40CB-8A87-2F315E99C2BB Q50051675-99CFE9A3-6668-4CAA-B943-C4475E3CCEE7 Q54211761-F9AC3F28-E6D2-4C75-A3D7-B0D411995A1A

P2860

Psychiatric Symptoms in Patients Receiving Dolutegravir.

http://www.wikidata.org/entity/Q37659135

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 07 December 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Psychiatric Symptoms in Patients Receiving Dolutegravir.

@en

Psychiatric Symptoms in Patients Receiving Dolutegravir.

@nl

type

label

Psychiatric Symptoms in Patients Receiving Dolutegravir.

@en

Psychiatric Symptoms in Patients Receiving Dolutegravir.

@nl

prefLabel

Psychiatric Symptoms in Patients Receiving Dolutegravir.

@en

Psychiatric Symptoms in Patients Receiving Dolutegravir.

@nl

P1433

Q37659135-30CAE65F-EFE5-45C1-996A-09DE8697CA31

P1476

Q37659135-2A380C0E-D456-4466-B26C-4CF5597A9F14

P2093

Q37659135-4E00891E-A338-41E3-A30D-F352B0BB35D3

Q37659135-73678D78-B32D-4B4E-8C51-7DD00A180B44

Q37659135-741BC32E-AEF1-481F-8D62-9BFBA1487059

Q37659135-94A0CA66-DBF5-452B-9CB9-1561AC2057BE

Q37659135-ADBAD5ED-F23E-468A-92B9-F164CF687D9C

Q37659135-CCE068D6-FE5D-475B-9EAE-F546BCC17B7B

Q37659135-E526451A-0776-4DCD-B4B1-DB8E09DFD6F1

Q37659135-EA2051FF-E96A-4118-B612-B540BA69FF9F

Q37659135-F1C86506-3F41-43BE-B6C7-D70161D0829B

Q37659135-F9ED37AF-256A-4FB5-A740-B0227916C88C

P2860

Q37659135-00DFDAB5-0653-40D9-8B4C-1405E59E4DBB

Q37659135-091D5D43-A753-4AC0-9F76-5DA61E5C4F7E

Q37659135-1062DBF4-850C-444E-B349-525338953277

Q37659135-20FFCE91-DA49-45DB-9EF6-11F4AE83657E

Q37659135-22988A87-6B54-4145-A456-C498CBC4F0C0

Q37659135-245ED141-B5C1-42EC-AA3E-8D25D1DAB938

Q37659135-38E4AA45-CCED-4A92-A3C1-25F5487906B3

Q37659135-3CD16782-6AC9-4D78-9279-3C5620558944

Q37659135-4BE19F9F-824E-4A3D-AF91-E33542DE6B0A

Q37659135-4FC6E6CC-AF29-47D8-A280-FDC036E61B5D

P304

Q37659135-E4A8DDF7-D308-42FC-8C18-024938947636

P31

Q37659135-E3E3F372-81DD-4C4C-88EF-33006C05D603

P356

Q37659135-705D177A-C41B-4BDE-8768-C80A8720F94E

P407

Q37659135-4818074E-7314-4455-9CD3-2EE9F2E0E04B

P433

Q37659135-DCAFB849-FC20-42A0-A35D-F26DD581FC10

P478

Q37659135-625AC02C-D501-4FCF-B274-178E167204BF

P50

Q37659135-F7C7F10E-A9DD-4A11-974E-FE969CCAFD61

P577

Q37659135-6F5664FD-73AE-47BB-9922-8DA924541085

P698

Q37659135-D22E90A2-9223-43DA-85F2-327A598F08E1

P932

Q37659135-E7082FE1-4276-4CD2-889D-746134011AA4

P356

QAI.0000000000001269

P1433

Journal of Acquired Immune Deficiency Syndromes

P1476

Psychiatric Symptoms in Patients Receiving Dolutegravir.

@en

P2093

Alan Winston

http://www.w3.org/2001/XMLSchema#string

Anna Fettiplace

http://www.w3.org/2001/XMLSchema#string

Jennifer Fusco

http://www.w3.org/2001/XMLSchema#string

Lloyd Curtis

http://www.w3.org/2001/XMLSchema#string

Michael Aboud

http://www.w3.org/2001/XMLSchema#string

Naomi Givens

http://www.w3.org/2001/XMLSchema#string

Ricky Hsu

http://www.w3.org/2001/XMLSchema#string

Romina Quercia

http://www.w3.org/2001/XMLSchema#string

Sarah Puccini

http://www.w3.org/2001/XMLSchema#string

Vani Vannappagari

http://www.w3.org/2001/XMLSchema#string

P2860

A systematic review of mental disorder, suicide, and deliberate self harm in lesbian, gay and bisexual people

HIV integrase inhibitors: a new era in the treatment of HIV.

Limitations and strengths of spontaneous reports data.

Neuropsychiatric manifestations of HIV infection and AIDS

Suicidal risk factors and completed suicide: meta-analyses based on psychological autopsy studies

Neurological and psychiatric adverse effects of antiretroviral drugs.

Associations of allostatic load with sleep apnea, insomnia, short sleep duration, and other sleep disturbances: findings from the National Health and Nutrition Examination Survey 2005 to 2008.

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.

Long-term safety from the raltegravir clinical development program.

Insomnia in HIV infection: a systematic review of prevalence, correlates, and management.

P304

423-431

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAI.0000000000001269

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P50

Chris M Stainsby

P577

2016-12-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27984559

http://www.w3.org/2001/XMLSchema#string

P932

5321108

http://www.w3.org/2001/XMLSchema#string